Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
Ранг среди акций #17990
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Цена акции
$1.69
Последняя синхронизация: 2026-09-02
Рыночная капитализация
$216.83M
Изменение (1 день)
3.38%
Изменение (1 год)
-66.03%
Страна
US
Торговля Organogenesis Holdings Inc. (ORGO)

Категория

Операционная маржа для Organogenesis Holdings Inc. (ORGO)
Операционная маржа на 2026 TTM: 0.00%
Согласно последним финансовым отчетам и цене акций Organogenesis Holdings Inc., текущая операционная маржа (TTM) составляет 0.00%. В конце 2026 она составила 0.00%.
История операционной маржи Organogenesis Holdings Inc. с 2026 по 2026
Операционная маржа на конец каждого года
Год Операционная маржа Изменить
Недостаточно данных для указанных дат.
Операционная маржа для аналогичных компаний или конкурентов
Компания Операционная маржа Разница в операционной марже Страна
0.00% -
DE
0.00% -
DE
0.00% -
JP
22.93% -
IN
0.00% -
CH
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.